Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22666415 | 1.00 | HCRTR1 (0.34) | HCRTR1HCRTR2KCNH2PDE10ACA1 | |
| SCHEMBL22666386 | 0.83 | HCRTR1 (0.36) | HCRTR1HCRTR2KCNH2PDE10A | |
| SCHEMBL22666292 | 0.83 | HCRTR1 (0.36) | HCRTR1HCRTR2KCNH2PDE10A | |
| SCHEMBL26350977 | 0.83 | MCHR1 (0.43) | HCRTR1HCRTR2KCNH2PDE10A | |
| SCHEMBL22666162 | 0.78 | FFAR4 (0.43) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL22666374 | 0.78 | PDE10A (0.34) | HCRTR1HCRTR2KCNH2PDE10A | |
| SCHEMBL22850822 | 0.78 | PDE10A (0.34) | HCRTR1HCRTR2KCNH2PDE10A | |
| SCHEMBL28803632 | 0.66 | LMNA (0.42) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL16742946 | 0.66 | KDM4E (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL2618741 | 0.65 | CYP2C9 (0.39) | CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020230800-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2020-11-19 | — | — | WO | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885KCNH2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.